Accelerated Biosciences, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Accelerated Biosciences, Inc. - overview
Established
2013
Location
Philadelphia, PA, US
Primary Industry
Biotechnology
About
Based in Pennsylvania, US, and founded in 2013 by CEO Yuta Lee, Accelerated Biosciences, Inc. specializes in the licensing of commercial-grade stem cell technologies for drug discovery, therapy development, and toxicology. The company offers a comprehensive offering, streamlining chemistry, manufacturing, and control (CMC) documentation with pre-prepared solutions, reducing time and effort for clients. Accelerated Biosciences' use of technology, such as TSC (therapeutic stem cells), is designed for cell therapy applications.
TSC exhibits a scalable capacity of 8x10¹⁷ doses at 100 million cells per dose. The platform's accelerated doubling time of 22 hours, coupled with stable karyotypes and human pathogen-free characteristics, sets it apart in the biotech landscape. The company's flagship products include TSC-NSC (Neural Stem Cells) and TSC-PPC (Pancreatic Progenitor Cells), a comprehensive set of cellular markers. The HLA-G, offer therapeutic solutions for the immune-privilege checkpoint, The product portfolio has 47 granted patents, 31 patents in process, and 7 patents, including US7642091B2, US7892534B2, US8163553B2, and US8497120B2.
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy
Website
www.acceleratedbio.com
Total Amount Raised
Subscriber access only
Accelerated Biosciences, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.